首页> 外文OA文献 >P862 Clinical benefit potentially evident with immunopharmacodynamic responses in prior-checkpoint failed metastatic melanoma patients treated with imprime PGG and pembrolizumab

【2h】

P862 Clinical benefit potentially evident with immunopharmacodynamic responses in prior-checkpoint failed metastatic melanoma patients treated with imprime PGG and pembrolizumab

机译：P862临床益处可能在先前检查点中的免疫力学响应可能明显，转移性的黑色瘤患者患者患者患者进行了缩写的pgg和pembrozumab

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Anissa Chan; Nandita Bose; Nadine Ottoson; Xiaohong Qiu; Ben Harrison; Richard Walsh; Paulette Mattson; Michele Gargano; Joanna Cox; Michael Chisamore; Mark Uhlik; Jeremy Graff;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. P862?Clinical benefit potentially evident with immunopharmacodynamic responses in prior-checkpoint failed metastatic melanoma patients treated with imprime PGG and pembrolizumab [J] . Anissa Chan, Nandita Bose, Nandita Bose, Journal for ImmunoTherapy of Cancer . 2020,第Suppla1期

机译：P862？在先前检查点中的免疫制药力反应可能明显潜在的临床益处失败的转移性黑色瘤患者，用英寸PGG和PEMBROLIZUAB治疗
2. P859?Association of immunopharmacodynamic responses of imprime PGG plus pembrolizumab with clinical benefit in metastatic triple negative breast cancer (TNBC) subjects failing front-line chemotherapy [J] . Nadine Ottoson, Nandita Bose, Anissa Chan, Journal for ImmunoTherapy of Cancer . 2020,第Suppla1期

机译：P859？Implime PGG Plus Pembolizumab与临床益处在转移性三重阴性乳腺癌（TNBC）受试者失败前线化疗
3. Response and clinical benefit assessment of the combination of the dectin-1 agonist imprime PGG and anti-PD-1 pembrolizumab in chemotherapy-resistant metastatic triple negative breast cancer (TNBC) [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：响应和临床效益评估Dectin-1激动剂PGG和抗PD-1 Pembrolizumab在化疗抗性转移性三重阴性乳腺癌（TNBC）中的组合
4. Preliminary results of a phase I/II clinical trial using in situ photoimmunotherapy combined with imiquimod for metastatic melanoma patients [C] . Xiaosong Li, Mark F. Naylor, Robert E. Nordquist, . 2010

机译：使用原位光免疫疗法联合咪喹莫特治疗转移性黑色素瘤患者的I / II期临床试验的初步结果
5. Associating Computed Tomography (CT) Imaging Response Criteria and Texture Analysis Measurements with Survival in Patients with Metastatic Melanoma Treated with Anti-angiogenic Therapy. [D] . Gray, Mark Russell. 2014

机译：将计算机断层扫描（CT）成像反应标准和纹理分析测量值与接受抗血管生成治疗的转移性黑色素瘤患者的生存率相关联。
6. A Phase III open-label randomized multicenter study of imprime pgg in combination with cetuximab in patients with kras wild type metastatic colorectal cancer [O] . Jeffrey A Meyerhardt, Michele M Grady, Jamie N Lowe, 2014

机译：krams野生型转移性结直肠癌患者中imprime pgg与西妥昔单抗联合进行的III期开放标签随机多中心研究
7. P859 Association of immunopharmacodynamic responses of imprime PGG plus pembrolizumab with clinical benefit in metastatic triple negative breast cancer (TNBC) subjects failing front-line chemotherapy [O] . Nadine Ottoson, Nandita Bose, Anissa Chan, 2020

机译：P859免疫制药权答案的关联PGG Plus Pembrolizumab在转移性三重阴性乳腺癌（TNBC）受试者失败前线化疗中的临床益处

P862 Clinical benefit potentially evident with immunopharmacodynamic responses in prior-checkpoint failed metastatic melanoma patients treated with imprime PGG and pembrolizumab

著录项

引文网络

相似文献

相关主题

期刊订阅